Luther King Capital Management (LKCM)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $499K | Sell |
800
-148
| -16% | -$101K | ﹤0.01% | 488 |
|
|
2026
Q1 | $732K | Hold |
948
| – | – | ﹤0.01% | 443 |
|
|
2025
Q4 | $732K | Buy |
948
+45
| +5% | +$30.6K | ﹤0.01% | 445 |
|
|
2025
Q3 | $508K | Buy |
903
+74
| +9% | +$41.8K | ﹤0.01% | 476 |
|
|
2025
Q2 | $435K | Buy |
829
+1
| +0.1% | +$558 | ﹤0.01% | 484 |
|
|
2025
Q1 | $525K | Hold |
828
| – | – | ﹤0.01% | 459 |
|
|
2024
Q4 | $590K | Sell |
828
-14
| -2% | -$11.7K | ﹤0.01% | 442 |
|
|
2024
Q3 | $885K | Buy |
842
+11
| +1% | +$12.2K | ﹤0.01% | 415 |
|
|
2024
Q2 | $873K | Buy |
831
+3
| +0.4% | +$2.91K | ﹤0.01% | 414 |
|
|
2024
Q1 | $797K | Hold |
828
| – | – | ﹤0.01% | 422 |
|
|
2023
Q4 | $727K | Hold |
828
| – | – | ﹤0.01% | 425 |
|
|
2023
Q3 | $681K | Hold |
828
| – | – | ﹤0.01% | 419 |
|
|
2023
Q2 | $595K | Sell |
828
-28
| -3% | -$21.6K | ﹤0.01% | 456 |
|
|
2023
Q1 | $703K | Sell |
856
-274
| -24% | -$207K | ﹤0.01% | 425 |
|
|
2022
Q4 | $815K | Sell |
1,130
-73
| -6% | -$53.9K | ﹤0.01% | 401 |
|
|
2022
Q3 | $829K | Sell |
1,203
-611
| -34% | -$385K | ﹤0.01% | 394 |
|
|
2022
Q2 | $1.07M | Buy |
1,814
+160
| +10% | +$104K | 0.01% | 381 |
|
|
2022
Q1 | $1.16M | Hold |
1,654
| – | – | 0.01% | 377 |
|
|
2021
Q4 | $1.04M | Sell |
1,654
-210
| -11% | -$129K | ﹤0.01% | 408 |
|
|
2021
Q3 | $1.13M | Hold |
1,864
| – | – | 0.01% | 394 |
|
|
2021
Q2 | $1.04M | Buy |
1,864
+1,436
| +336% | +$728K | 0.01% | 412 |
|
|
2021
Q1 | $203K | Hold |
428
| – | – | ﹤0.01% | 538 |
|
|
2020
Q4 | $207K | Sell |
428
-102
| -19% | -$55.1K | ﹤0.01% | 536 |
|
|
2020
Q3 | $297K | Buy |
530
+32
| +6% | +$19.4K | ﹤0.01% | 468 |
|
|
2020
Q2 | $311K | Buy |
+498
| New | +$283K | ﹤0.01% | 451 |
|
|
2018
Q1 | – | Sell |
-825
| Closed | -$310K | – | 534 |
|
|
2017
Q4 | $310K | Hold |
825
| – | – | ﹤0.01% | 460 |
|
|
2017
Q3 | $369K | Buy |
825
+145
| +21% | +$69K | ﹤0.01% | 431 |
|
|
2017
Q2 | $334K | Sell |
680
-50
| -7% | -$21.9K | ﹤0.01% | 428 |
|
|
2017
Q1 | $283K | Sell |
730
-295
| -29% | -$109K | ﹤0.01% | 452 |
|
|
2016
Q4 | $376K | Sell |
1,025
-375
| -27% | -$143K | ﹤0.01% | 427 |
|
|
2016
Q3 | $563K | Sell |
1,400
-70
| -5% | -$28.1K | 0.01% | 388 |
|
|
2016
Q2 | $513K | Buy |
1,470
+140
| +11% | +$53.9K | 0.01% | 397 |
|
|
2016
Q1 | $479K | Buy |
1,330
+350
| +36% | +$144K | ﹤0.01% | 402 |
|
|
2015
Q4 | $532K | Sell |
980
-220
| -18% | -$119K | 0.01% | 408 |
|
|
2015
Q3 | $558K | Sell |
1,200
-160
| -12% | -$85.9K | 0.01% | 404 |
|
|
2015
Q2 | $694K | Buy |
1,360
+25
| +2% | +$12.2K | 0.01% | 403 |
|
|
2015
Q1 | $603K | Sell |
1,335
-110
| -8% | -$46.6K | 0.01% | 411 |
|
|
2014
Q4 | $593K | Hold |
1,445
| – | – | ﹤0.01% | 419 |
|
|
2014
Q3 | $521K | Buy |
1,445
+275
| +24% | +$92.2K | ﹤0.01% | 451 |
|
|
2014
Q2 | $330K | Buy |
1,170
+270
| +30% | +$80K | ﹤0.01% | 487 |
|
|
2014
Q1 | $270K | Buy |
+900
| New | +$277K | ﹤0.01% | 485 |
|
Other funds holding REGN
Luther King Capital Management (LKCM)'s REGN Position: Q2 2026 in Review
Luther King Capital Management (LKCM) reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2026, selling an estimated $101K and leaving 800 shares worth $499K. The position accounts for ﹤0.01% of the portfolio, ranked #488.
Luther King Capital Management (LKCM) first reported a position in REGN in Q1 2014 and has held it in 41 quarters since. The position peaked at $1.16M in Q1 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Luther King Capital Management (LKCM) held 800 shares of Regeneron Pharmaceuticals worth $499K as of Q2 2026.
- Luther King Capital Management (LKCM) sold 148 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $101K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Luther King Capital Management (LKCM)'s portfolio in Q2 2026, its #488 holding.
- Luther King Capital Management (LKCM) first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 41 quarters since.
- Luther King Capital Management (LKCM)'s Regeneron Pharmaceuticals position peaked at $1.16M in Q1 2022.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Luther King Capital Management (LKCM)'s 13F filing for Q2 2026, filed 10 Aug 2026.